ALPHA GENOMIX LABORATORIES, INC. v. SHANE CRANDALL

CourtCourt of Appeals of Georgia
DecidedJuly 27, 2023
DocketA23A1096
StatusPublished

This text of ALPHA GENOMIX LABORATORIES, INC. v. SHANE CRANDALL (ALPHA GENOMIX LABORATORIES, INC. v. SHANE CRANDALL) is published on Counsel Stack Legal Research, covering Court of Appeals of Georgia primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
ALPHA GENOMIX LABORATORIES, INC. v. SHANE CRANDALL, (Ga. Ct. App. 2023).

Opinion

FIRST DIVISION BARNES, P. J., LAND and, WATKINS, JJ.

NOTICE: Motions for reconsideration must be physically received in our clerk’s office within ten days of the date of decision to be deemed timely filed. https://www.gaappeals.us/rules

July 27, 2023

In the Court of Appeals of Georgia A23A1096. ALPHA GENOMIX LABORATORIES, INC. et al v. CRANDALL.

BARNES, Presiding Judge.

Shane Crandall sued Alpha Genomix Laboratories, Inc. (“Alpha”) and

Consultative Genomics, LLC (“ConGen”), alleging that they owed him severance

benefits under his employment contract. Following a bench trial, the trial court

entered final judgment in favor of Crandall on his claims for breach of contract and

awarded him damages. On appeal, the defendants contend that the judgment should

be reversed because Crandall’s employment contract failed for lack of consideration;

the employment contract was unenforceable because Alpha’s CEO and Crandall

violated their fiduciary duties and acted in bad faith in executing the contract; there

was no “change in control” that triggered the payment of severance benefits under the employment contract; ConGen did not assume liability for breach of the employment

contract when it acquired all of Alpha’s shares; Crandall was barred from bringing

suit under a contractual indemnification provision; and the severance provision of the

employment contract was invalid because it violated the federal Eliminating

Kickbacks in Recovery Act (“EKRA”), 18 USC § 220.

For the reasons discussed below, we vacate the judgment in part and remand

for the trial court to consider under the proper legal framework whether ConGen

assumed liability for breach of the employment contract when it acquired the shares

of Alpha. On remand, the trial court also should address two other issues that were

raised below but were not ruled on by the court in its judgment: whether Crandall’s

claims are barred by the contractual indemnification provision or by EKRA. We

affirm the judgment in all other respects.

Construed in favor of the judgment,1 the evidence presented at the bench trial

showed that Alpha is a medical testing laboratory located in Peachtree Corners,

Georgia, which was acquired by ConGen in December 2018. Before the acquisition,

Alpha was owned by 28 shareholders. The shareholders did not take part in the day-

1 See Gibson v. Gibson, 301 Ga. 622, 624 (801 SE2d 40) (2017).

2 to-day operations of Alpha and did not vote on operational issues like the execution

of contracts. One of Alpha’s shareholders, Hani El Shawa, served as its CEO and on

its three-member Board of Directors. Alpha’s largest shareholder, Richard Sasnett,

served as its Executive Vice President of Sales and as a Board member. Prior to

December 2018, Alpha had no bylaws governing its officers and directors.

Crandall’s Employment at Alpha before the ConGen Acquisition. In April

2016, Alpha hired Crandall to serve as an Area Sales Director. While serving in that

position, Crandall reported to Sasnett. In the summer of 2017, Crandall engaged in

discussions with El Shawa, Sasnett, and another Area Sales Director about

developing and marketing new product lines. As a result of those discussions, El

Shawa and Sasnett made the decision to promote Crandall to a newly created position

of National Sales Director — Oncology & Women’s Health, where he would continue

to report to Sasnett but would have expanded job responsibilities. In his new position,

Crandall would lead sales representatives in their efforts to identify physicians who

had patients who could benefit from Alpha’s testing capabilities. However, Crandall

would not have authority to hire or fire employees, set employees’ salaries, or sign

employment contracts on behalf of Alpha.

3 In light of his promotion, the parties agreed that Alpha would provide Crandall

with a new employment agreement that included an increase in salary and

commissions. Additionally, because there was talk at Alpha that it might be acquired

by another entity or become a publicly traded company, the parties agreed that

Crandall’s new employment agreement would include a severance provision

addressing a change in control in the management of the company.

Crandall began serving in his new National Sales Director position based on

assurances from El Shawa and Sasnett that his written employment agreement soon

would be finalized, with its terms and conditions applied retroactively. El Shawa

provided Crandall with several drafts of the employment agreement over the ensuing

months. The draft agreements were prepared by Alpha’s counsel, who also were

shareholders of the company. All three of Alpha’s Board members (El Shawa,

Sasnett, and the third member) were aware of the negotiations and discussed with

legal counsel the terms and conditions to include in Crandall’s employment

agreement.

In May 2018, El Shawa emailed Crandall the version of the employment

agreement that ultimately was executed by the parties. After several more months

passed in which Crandall continued to inquire about when his employment agreement

4 would be executed, El Shawa called Crandall to his office on December 12, 2018. On

that date, El Shawa, in his capacity as Alpha’s CEO, and Crandall signed the

employment agreement (“Employment Agreement” or “Agreement”). El Shawa,

Sasnett, and other members of Alpha’s executive management team also signed new

employment agreements at the same time as Crandall.

Crandall’s Employment Agreement included an increase in salary and

commissions in return for Crandall serving in his new National Sales Director

position. The Employment Agreement established an initial two-year term for

Crandall’s employment in his new position, subject to renewal, and included several

provisions addressing termination of Crandall’s employment and severance pay in the

event of his termination. Among other severance provisions, the Employment

Agreement included a provision pertaining to a change in control in management at

Alpha that is at the center of the dispute in this case (“Change-in-Control Provision”).

The Change-in-Control Provision stated:

7.5 By Employee upon a Change of Control. (a) In the event of a Change in Control (as defined below), Employee [Crandall] shall have the right to terminate his employment hereunder by giving a written notice of termination to the Company [Alpha] within ninety (90) days after the date a Change in Control occurs. If Company terminates

5 Employee’s employment (or provides a notice of termination to Employee) within the ninety (90) day period after the date a Change in Control occurs and such termination is not for Cause pursuant to Section 7.4 above, such termination shall have the same effect as if the Employee had submitted his notice of termination to the Company pursuant to this Section 7.5. The parties agree that, if Employee terminates his employment pursuant to this Section 7.5 (or is deemed to have terminated his employment pursuant to this Section 7.5 as provided in the previous sentence), Employee shall be entitled to the following benefits:

(i) Base Salary. Employee shall receive his then current Base Salary for a period of twelve (12) months following the Termination Date payable in the same manner as it was being paid as of the Termination Date (subject to withholding of all applicable taxes).

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Bullington v. Union Tool Corp.
328 S.E.2d 726 (Supreme Court of Georgia, 1985)
Bowen Builders Group, Inc. v. Reed
555 S.E.2d 745 (Court of Appeals of Georgia, 2001)
ROYAL CROWN COMPANIES v. McMahon
359 S.E.2d 379 (Court of Appeals of Georgia, 1987)
Brown Transport Corp. v. Street
391 S.E.2d 699 (Court of Appeals of Georgia, 1990)
Coleman v. Daimlerchrysler Services of North America, LLC
623 S.E.2d 189 (Court of Appeals of Georgia, 2005)
Speed v. Muhanna
619 S.E.2d 324 (Court of Appeals of Georgia, 2005)
Williamson v. STRICKLAND & SMITH, INC.
673 S.E.2d 858 (Court of Appeals of Georgia, 2009)
Mon Ami International, Inc. v. Gale
592 S.E.2d 83 (Court of Appeals of Georgia, 2003)
Jerry Dickerson Presents, Inc. v. Concert/Southern Chastain Promotions
579 S.E.2d 761 (Court of Appeals of Georgia, 2003)
BDI Laguna Holdings, Inc. v. Marsh
689 S.E.2d 39 (Court of Appeals of Georgia, 2009)
Edwards v. Grapefields, Inc.
599 S.E.2d 489 (Court of Appeals of Georgia, 2004)
Shelby Insurance v. Ford
454 S.E.2d 464 (Supreme Court of Georgia, 1995)
Tattersall Club Corp. v. White
501 S.E.2d 851 (Court of Appeals of Georgia, 1998)
Glisson v. Global Security Services, LLC
653 S.E.2d 85 (Court of Appeals of Georgia, 2007)
BAARS v. Freeman
708 S.E.2d 273 (Supreme Court of Georgia, 2011)
Woods v. Hall
726 S.E.2d 596 (Court of Appeals of Georgia, 2012)
Federal Deposit Insurance Corp. v. Loudermilk
761 S.E.2d 332 (Supreme Court of Georgia, 2014)
Mosaic Business Advisory Services, Inc. v. Stone
784 S.E.2d 426 (Court of Appeals of Georgia, 2016)
City of Atlanta v. Mays
801 S.E.2d 1 (Supreme Court of Georgia, 2017)
Gibson v. Gibson
801 S.E.2d 40 (Supreme Court of Georgia, 2017)

Cite This Page — Counsel Stack

Bluebook (online)
ALPHA GENOMIX LABORATORIES, INC. v. SHANE CRANDALL, Counsel Stack Legal Research, https://law.counselstack.com/opinion/alpha-genomix-laboratories-inc-v-shane-crandall-gactapp-2023.